Sofosbuvir/Velpatasvir — Total revenues
Gilead Sciences Sofosbuvir/Velpatasvir — Total revenues increased by 2.9% to $283.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 18.2%, from $346.00M to $283.00M. Over 3 years (FY 2022 to FY 2025), Sofosbuvir/Velpatasvir — Total revenues shows a downward trend with a -6.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong market adoption and sustained demand for the therapy, while a decrease may signal increased competition, patent expirations, or a shift in the patient population requiring treatment.
Detailed definition
This metric represents the total gross revenue generated from the sale of a specific direct-acting antiviral medication...
Peer comparison
Comparable to revenue streams from specialized antiviral or chronic disease therapeutic product lines at other major pharmaceutical companies.
gild_segment_sofosbuvir_velpatasvir_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $382.50M | $382.50M | $382.50M | $382.50M | $384.25M | $384.25M | $384.25M | $384.25M | $405.00M | $476.00M | $385.00M | $330.00M | $346.00M | $342.00M | $309.00M | $275.00M | $283.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.5% | +0.0% | +0.0% | +0.0% | +5.4% | +17.5% | -19.1% | -14.3% | +4.8% | -1.2% | -9.6% | -11.0% | +2.9% |
| YoY Change | — | — | — | — | +0.5% | +0.5% | +0.5% | +0.5% | +5.4% | +23.9% | +0.2% | -14.1% | -14.6% | -28.2% | -19.7% | -16.7% | -18.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's sofosbuvir/velpatasvir — total revenues?
- Gilead Sciences (GILD) reported sofosbuvir/velpatasvir — total revenues of $283.00M in Q1 2026.
- How has Gilead Sciences's sofosbuvir/velpatasvir — total revenues changed year-over-year?
- Gilead Sciences's sofosbuvir/velpatasvir — total revenues decreased by 18.2% year-over-year, from $346.00M to $283.00M.
- What is the long-term trend for Gilead Sciences's sofosbuvir/velpatasvir — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's sofosbuvir/velpatasvir — total revenues has grown at a -6.0% compound annual growth rate (CAGR), from $1.53B to $1.27B.
- What does sofosbuvir/velpatasvir — total revenues mean?
- The total sales revenue generated from the company's specific hepatitis C antiviral medication.